BMEYE and Masimo have reported that BMEYE has received CE Mark certification and the European launch of the ccNexfin, the first noninvasive cardiovascular monitor with Masimo Rainbow SET Pulse CO-Oximetry technology.

The combination of two noninvasive technologies, BMEYE for cardiovascular monitoring and Masimo Rainbow SET for hemoglobin and oxygen saturation monitoring, provides real-time, beat-to-beat measurements of cardiac, circulatory, and pulmonary parameters, which may enable clinicians to detect impending cardiovascular crisis before organ injury ensues.

The ccNexfin with Masimo Rainbow SET offers some of the most advanced cardiovascular monitoring capabilities. It utilizes a single sensor finger cuff (BMEYE) and finger sensor (Masimo Rainbow SET) to capture and continuously measure beat-to-beat blood pressure and many other cardiac effects.

The integration of ccNexfin and Masimo Rainbow SET technologies into the emergency department, intensive care units, and anesthesiology care areas has the potential to facilitate earlier diagnosis and the delivery of protocol- and goal-directed therapies that improve patient safety and clinical outcomes.

Rob de Ree, CEO of BMEYE, said: “ccNexfin is a noninvasive, beat-to-beat, and user friendly cardiovascular monitor that delivers a patient’s full hemodynamic profile based on real-time data. Masimo Rainbow SET Pulse CO-Oximetry plays an integral role in the delivery of this hemodynamic data stream by providing critical information about oxygen delivery at the tissue level, which is an essential component of accurate hemodynamic assessment.”

Joe Kiani, founder and CEO of Masimo, said: “The risks and costs associated with invasive hemodynamic monitoring techniques leaves many high-risk patients underserved at a time when assessing hemodynamic stability is most needed. The synergistic combination of BMEYE and Rainbow SET means that continuous, noninvasive hemodynamic monitoring can benefit more patients at all points along the care path.”